Enlivex (ENLV) Earnings Date & Reports

Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis... Show more

Industry: #Medical Specialties

Get AI intraday signals

A.I. Advisor

published Earnings

ENLV is expected to report earnings to fall 9.68% to -28 cents per share on December 07

Q3'26

Est.

$-0.28

Q2'26

Missed

by $0.01

Q1'26

Beat

by $0.86

Q4'25

Est.

$-0.14

Q3'25

Beat

by $0.03

The last earnings report on August 24 showed earnings per share of -31 cents, missing the estimate of -30 cents. With 365.41K shares outstanding, the current market capitalization sits at 8.99M.

View a ticker or compare two or three

ENLV

Daily Signal:

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

View AI-Driven Trading for ENLV